NCT05194735 — Alaunos Therapeutics cancer immunotherapy trial
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Registry record
| Registry ID | NCT05194735 ↗ |
|---|---|
| Lead sponsor | Alaunos Therapeutics |
| Collaborators | — |
| Phase | Phase 1/2 |
| Status | Terminated |
| Indication | Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer |
| Enrollment | 8 participants (target) |
| Start date | 2022-04-04 |
| Primary completion | 2023-09-30 |
| Last registry update | 9 Nov 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05194735), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05194735?
NCT05194735 (Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Alaunos Therapeutics.
Is NCT05194735 recruiting?
As of the 2026-11-09 registry update, NCT05194735 is listed as "Terminated". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05194735?
The lead sponsor is Alaunos Therapeutics.
What condition does NCT05194735 study?
The registered conditions are Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer. Primary completion is listed as 2023-09-30.
Are results available for NCT05194735?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05194735.
Back to the full neoantigen vaccine trial tracker — 105 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.